AngioDynamics Acquires FlowMedica Benephit(R) Renal Therapy Product LineQUEENSBURY, N.Y.--(BUSINESS WIRE)--Jan. 12, 2009--AngioDynamics Inc. (NASDAQ: ANGO), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, announced today that it has purchased certain assets of privately-held FlowMedica Inc., a leader in the emerging field of Targeted Renal Therapy^™ (TRT^®). The transaction was structured as an asset purchase under which AngioDynamics will pay $1.75 million in cash for the assets of the business plus a contingent payment based on fiscal 2011 sales of Benephit products.

Pioneered by FlowMedica, TRT is a therapeutic approach that delivers drugs directly to the kidneys in order to prevent and treat acute kidney injury (AKI). AKI often results from many common interventional and surgical procedures, and is a significant problem in high renal risk patients such as the elderly and diabetics. Benephit infusion products deliver therapeutic agents directly into both renal arteries through dedicated infusion catheter and sheath systems while allowing simultaneous interventional coronary, peripheral, endovascular and surgical procedures. TRT can also be employed for stand-alone renal drug delivery in other hospital settings when desired. The Benephit systems have been granted 510(k) clearance from the FDA and the CE Mark, and are commercially available.

"With dramatically increasing volumes of interventional procedures among the high-risk patient population, the prevention and treatment of acute kidney injury is a major area of concern for caregivers," said Paul Teirstein, M.D., Chief of Cardiology and Director of Interventional Cardiology at the Scripps Clinic in La Jolla, California, and Visiting Professor of Medicine at Columbia University Medical Center. "While employing the Benephit systems in numerous high-risk cases, I have found it simple to use and very effective in providing a significant improvement in clinical outcomes for my patients."

"This purchase is an example of AngioDynamics' acquisition strategy to focus on small transactions that extend our product offerings, can be sold by our sales force and have near-term revenue potential," said Eamonn Hobbs, President and CEO of AngioDynamics. "We believe FlowMedica's Benephit infusion systems have the potential to address the needs of patients at risk for AKI that result from common medical procedures and is also associated with certain medical conditions. This represents a significant large and unmet market opportunity with an annual value of several hundred million dollars. We intend to begin marketing the systems through our Peripheral Vascular sales team. If we are successful, this product line could become a significant contributor to our financial results in the years ahead."

AngioDynamics has hired 10 FlowMedica employees and plans to continue to operate from FlowMedica's Fremont, California office. In fiscal year 2009, the Company expects the FlowMedica acquisition to have a modest impact on net sales and to be $0.01 per share dilutive to earnings. In fiscal 2010, the acquisition is expected to produce incremental sales of $3 million, and to be accretive to earnings.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation and irreversible electroporation resection systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

Safe Harbor

This press release contains "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Investors can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements contain words such as "expect," "reaffirm," "anticipate," "plan," "believe," "estimate," "may," "will," "predict," "project," "might," "intend," "potential," "could," "would," "should," "estimate," "seek," "continue," "pursue," or "our future success depends," or the negative or other variations thereof or comparable terminology, are intended to identify such forward-looking statements. In particular, they include statements relating to, among other things, future actions, strategies, future performance and future financial results of the Company. These forward-looking statements are based on current expectations and projections about future events.

Investors are cautioned that forward-looking statements are not guarantees of future performance or results, and involve risks and uncertainties that cannot be predicted or quantified and, consequently, the actual performance or results of the Company may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the factors described from time to time in the Company's reports filed with the SEC, including the Company's Form 10-K for the fiscal year ended May 31, 2008, financial community and rating agency perceptions of the Company; the effects of economic, credit and capital market conditions on the economy in general, and on medical device companies in particular; domestic and foreign health care reforms and governmental laws and regulations; third-party relations and approvals, technological advances and patents attained by competitors; and challenges inherent in new product development, including obtaining regulatory approvals. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, and the effects on pricing from group purchasing organizations and competition, may affect the actual results achieved by the Company.

Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. The Company disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date stated, or if no date is stated, as of the date of this document.

CONTACT: AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
jgersuk@AngioDynamics.com
or
EVC Group, Inc.


Jenifer Kirtland, 415-896-6820 (Investor Relations)
jkirtland@evcgroup.com
Doug Sherk, 415-896-6820 (Investor Relations)
dsherk@evcgroup.com
Chris Gale, 646-201-5431 (Media)


cgale@evcgroup.com

Source: AngioDynamics, Inc.